首頁 > 市場調查報告書 > 製藥

神經疾病

多發性硬化症藥物市場規模、佔有率和成長分析（按藥物類別、通路、給藥途徑和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898601

多發性硬化症藥物市場規模、佔有率和成長分析（按藥物類別、通路、給藥途徑和地區分類）—產業預測（2026-2033 年）

Multiple Sclerosis Drugs Market Size, Share, and Growth Analysis, By Drug Class (Immunosuppressant and Immunomodulators), By Distribution Channel (Hospital, Pharmacy), By Mode of Administration, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，多發性硬化症治療市場規模將達到 296.2 億美元，到 2025 年將成長至 308.9 億美元，到 2033 年將成長至 432.7 億美元，預測期（2026-2033 年）的複合年成長率為 4.3%。

由於多發性硬化症 (MS) 的盛行率和疾病負擔日益加重，且該疾病會影響多種生理功能，因此多發性硬化症治療市場正經歷顯著成長。對有效治療方法的需求不斷成長，推動了創新化療藥物的需求。各大製藥公司正大力投資研發新型治療方法，藥物製劑方面也取得了最新進展，例如用於家庭治療的鼻內抗 CD3 單株抗體。此外，旨在改善治療可近性的新產品上市和政府措施也進一步推動了市場擴張。這些因素，加上對新療法的持續追求，使得多發性硬化症治療市場前景廣闊，為產業相關人員提供了盈利的機會。

多發性硬化症藥物市場促進因素

全球多發性硬化症 (MS) 的盛行率不斷上升，導致對 MS 藥物的需求顯著成長。數以百萬計的人飽受這種疾病的折磨，尤其是在已開發地區，因此迫切需要能夠有效延緩和控制疾病進展的創新治療方法。隨著人們對 MS 的認知不斷提高以及診斷能力的進步，越來越多的患者被發現，從而擴大了需要新治療方案的患者群體。這種對有效治療方案日益成長的需求正在重塑 MS 藥物的市場格局，並凸顯了推動醫療技術發展的迫切性。

限制多發性硬化症藥物市場的因素

多發性硬化症 (MS) 的高昂治療費用是市場擴張的一大障礙。包括化療和各種口服藥物在內的疾病修正治療價格通常價格分佈，使得沒有全面醫療保險的患者難以負擔。這項經濟挑戰在中低收入國家尤其嚴峻，這些國家的醫療體系往往缺乏足夠的資源來提供這些先進的療法。因此，許多 MS 患者無法獲得所需的治療，這不僅限制了整體市場潛力，也限制了更多患者群體可獲得的治療方案。

多發性硬化症治療藥物市場趨勢

在多發性硬化症藥物市場，個人化醫療和基於生物標記的治療方法正迅速發展。遺傳學和分子生物學的進步推動了特定生物標記的識別，從而改變了治療策略，使醫療服務提供者能夠預測疾病進展並根據患者的個別特徵量身定做治療方案。這種轉變不僅提高了治療效果，而且透過針對每位患者獨特的生物學特徵調整治療方案，最大限度地減少了副作用。隨著對個人化醫療的日益重視，製藥公司正大力投資研發，為滿足多發性硬化症患者的多樣化需求而開發創新解決方案。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Biogen Inc.（United States）
Roche Holdings AG（Switzerland）
Novartis AG（Switzerland）
Sanofi SA（France）
Merck & Co., Inc.（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Bayer AG（Germany）
Pfizer Inc.（United States）
GlaxoSmithKline plc（United Kingdom）
AbbVie Inc.（United States）
Johnson & Johnson Services, Inc.（United States）
Celgene Corporation（United States）
Bristol-Myers Squibb Company（United States）
Mitsubishi Tanabe Pharma Corporation（Japan）
Biogen Idec International GmbH（Switzerland）
Genzyme Corporation（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Merck KGaA（Germany）
Mylan NV（United States）

結論與建議

簡介目錄

Product Code: SQMIG35I2199

Multiple Sclerosis Drugs Market size was valued at USD 29.62 Billion in 2024 and is poised to grow from USD 30.89 Billion in 2025 to USD 43.27 Billion by 2033, growing at a CAGR of 4.3% during the forecast period (2026-2033).

The market for multiple sclerosis (MS) drugs is experiencing significant growth due to the rising prevalence and burden of the disease, which impacts various bodily functions. This growing need for effective therapies is prompting increased demand for innovative chemotherapeutics. Major pharmaceutical companies are heavily investing in research and development to create novel treatments, with recent advancements in drug formulations, including intranasal anti-CD3 monoclonal antibodies designed for at-home use. Additionally, product launches and government initiatives aimed at improving treatment accessibility are further propelling market expansion. These factors, coupled with the ongoing push for new therapeutic options, indicate a promising outlook for the multiple sclerosis drug market, presenting lucrative opportunities for industry stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Sclerosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Sclerosis Drugs Market Segments Analysis

Global Multiple Sclerosis Drugs Market is segmented by Type, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Immunomodulators, Interferons, Immunosuppressants and Other types. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Multiple Sclerosis Drugs Market

The rising incidence of multiple sclerosis (MS) globally significantly propels the demand for multiple sclerosis drugs. With millions of individuals affected by this condition, particularly in more developed regions, there is a pressing need for innovative treatments to effectively address and manage the progression of the disease. As awareness of MS expands and diagnostic capabilities improve, more patients are being identified, thereby increasing the overall patient population that necessitates new therapeutic options. This growing demand for effective treatment solutions is shaping the landscape of the multiple sclerosis drugs market, highlighting the urgency for advancements in medical therapies.

Restraints in the Multiple Sclerosis Drugs Market

The high cost associated with Multiple Sclerosis (MS) treatments presents a significant obstacle to market expansion. Disease-modifying therapies, including chemotherapy and various oral medications, are frequently priced at premium levels, rendering them inaccessible for patients lacking comprehensive insurance. This financial challenge is particularly severe in low- and middle-income nations, where healthcare systems often lack the necessary resources to provide such advanced treatments. As a result, many individuals suffering from MS are unable to receive the care they need, hindering overall market potential and limiting the advancement of therapeutic options available to a broader patient population.

Market Trends of the Multiple Sclerosis Drugs Market

The Multiple Sclerosis drugs market is increasingly embracing the trend of personalized medicine and biomarker-based therapies. Fueled by advancements in genetics and molecular biology, the ability to identify specific biomarkers is transforming treatment strategies, enabling healthcare providers to predict disease progression and tailor therapies to individual patient profiles. This shift not only enhances treatment efficacy but also minimizes adverse effects by aligning therapeutic approaches with the unique biological characteristics of each patient. As the focus on customized care grows, pharmaceutical companies are investing heavily in research and development, paving the way for innovative solutions that cater to the diverse needs of those living with Multiple Sclerosis.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Multiple Sclerosis Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
Immunomodulators
Interferons
Immunosuppressants
Other types

Global Multiple Sclerosis Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral
Others

Global Multiple Sclerosis Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Distribution Channels

Global Multiple Sclerosis Drugs Market Size & CAGR (2026-2033)

North America (Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holdings AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitsubishi Tanabe Pharma Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Idec International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genzyme Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments